HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line

SIMPLE SUMMARY: Lapatinib is a tyrosine kinase inhibitor widely used as a treatment for a Human Epidermal growth factor Receptor 2 (HER2) (+) breast cancer patients. However, when resistance is acquired through continued exposure, and it is associated with a poor prognosis for patients. In this stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hye Jin, Shin, Seungho, Kang, Jinho, Han, Ki-Cheol, Kim, Yeul Hong, Bae, Jeoung-Won, Park, Kyong Hwa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564044/
https://www.ncbi.nlm.nih.gov/pubmed/32942617
http://dx.doi.org/10.3390/cancers12092630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564044/
https://www.ncbi.nlm.nih.gov/pubmed/32942617
http://dx.doi.org/10.3390/cancers12092630

Ejemplares similares